[go: up one dir, main page]

HUP0000979A1 - FK-506 jelű vegyületet és származékait tartalmazó gyógyászati készítmények - Google Patents

FK-506 jelű vegyületet és származékait tartalmazó gyógyászati készítmények

Info

Publication number
HUP0000979A1
HUP0000979A1 HU0000979A HUP0000979A HUP0000979A1 HU P0000979 A1 HUP0000979 A1 HU P0000979A1 HU 0000979 A HU0000979 A HU 0000979A HU P0000979 A HUP0000979 A HU P0000979A HU P0000979 A1 HUP0000979 A1 HU P0000979A1
Authority
HU
Hungary
Prior art keywords
derivatives
pharmaceutical compositions
compositions containing
substance
water
Prior art date
Application number
HU0000979A
Other languages
English (en)
Inventor
Rinta Ibuki
Norio Ohnishi
Fumio Shimojo
Toshihiko Toyoda
Satoshi Ueda
Masayuki Yamanaka
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Publication of HUP0000979A1 publication Critical patent/HUP0000979A1/hu
Publication of HUP0000979A3 publication Critical patent/HUP0000979A3/hu
Publication of HU226163B1 publication Critical patent/HU226163B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)

Abstract

A találmány tárgya FK-506 jelű vegyületet vagy gyógyászatilagelfogadható sóját, egy olajszerű anyagot, egy felületaktív anyagot,egy hidrofób (víztaszító) anyagot, vizet, és tetszés szerint egy, apH-t szabályozó anyagot tartalmazó gyógyászati készítmény, amelynekfokozott a stabilitása, felszívódási képessége, és/vagy alacsony abőrre gyakorolt izgató hatása. Ó
HU0000979A 1997-02-20 1998-02-18 Pharmaceutical compositions containing fk-506 and derivatives thereof HU226163B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP3617297 1997-02-20
JP25635797 1997-09-22
PCT/JP1998/000665 WO1998036747A1 (en) 1997-02-20 1998-02-18 Pharmaceutical composition

Publications (3)

Publication Number Publication Date
HUP0000979A1 true HUP0000979A1 (hu) 2000-10-28
HUP0000979A3 HUP0000979A3 (en) 2002-10-28
HU226163B1 HU226163B1 (en) 2008-05-28

Family

ID=26375217

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000979A HU226163B1 (en) 1997-02-20 1998-02-18 Pharmaceutical compositions containing fk-506 and derivatives thereof

Country Status (20)

Country Link
US (1) US6387918B1 (hu)
EP (1) EP0977565B1 (hu)
JP (1) JP3396888B2 (hu)
KR (1) KR100490357B1 (hu)
CN (1) CN1178656C (hu)
AR (1) AR011846A1 (hu)
AT (1) ATE237325T1 (hu)
AU (1) AU727337B2 (hu)
BR (1) BR9807234B1 (hu)
CA (1) CA2282345C (hu)
DE (1) DE69813542T2 (hu)
DK (1) DK0977565T3 (hu)
EA (1) EA003580B1 (hu)
ES (1) ES2193515T3 (hu)
HU (1) HU226163B1 (hu)
IL (1) IL131298A (hu)
NO (1) NO325103B1 (hu)
PT (1) PT977565E (hu)
TW (1) TW450810B (hu)
WO (1) WO1998036747A1 (hu)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3732525B2 (ja) * 1998-04-27 2006-01-05 アステラス製薬株式会社 医薬組成物
GB9817064D0 (en) * 1998-08-05 1998-10-07 Fujisawa Pharmaceutical Co New use
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition
NZ532769A (en) 2001-11-29 2005-12-23 3M Innovative Properties Co Pharmaceutical formulations comprising an immune response modifier
US8163726B2 (en) 2002-09-18 2012-04-24 University Of Pennsylvania Method of inhibiting choroidal neovascularization
PL1663217T3 (pl) 2003-08-29 2010-12-31 Lifecycle Pharma As Stałe dyspersje zawierające takrolimus
DK1663216T3 (da) 2003-08-29 2012-02-20 Veloxis Pharmaceuticals As Tacrolimus-holdige sammensætninger med modificeret frigivelse
CN102144961A (zh) * 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
BRPI0607606B1 (pt) 2005-02-09 2021-06-22 Santen Pharmaceutical, Co., Ltd. Formulação líquida
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
US7672006B2 (en) * 2006-02-22 2010-03-02 Xerox Corporation Multi-marking engine printing platform
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
WO2007120592A1 (en) * 2006-04-10 2007-10-25 Merck & Co., Inc. Cgrp antagonist salt
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
DK2167033T3 (en) 2007-05-30 2017-08-14 Veloxis Pharmaceuticals As Once daily oral dosage form comprising tacrolism
US12403095B2 (en) 2008-05-30 2025-09-02 Veloxis Pharmaceuticals, Inc. Stabilized tacrolimus composition
CN102176913B (zh) * 2008-10-08 2014-08-13 高田制药株式会社 外用的他克莫司制剂
PT2575769T (pt) 2010-02-17 2016-09-22 Veloxis Pharmaceuticals As Composição de tacrolímus estabilizada
JP5674786B2 (ja) * 2010-07-23 2015-02-25 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
WO2012011192A1 (ja) 2010-07-23 2012-01-26 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
US20140322300A1 (en) * 2011-12-07 2014-10-30 Hisamitsu Pharmaceutical Co., Inc. Patch
WO2013111817A1 (ja) * 2012-01-25 2013-08-01 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
AU2016308568A1 (en) 2015-08-19 2018-02-22 Vivus Llc Pharmaceutical formulations
JP6997222B2 (ja) 2017-06-23 2022-01-17 ザ プロクター アンド ギャンブル カンパニー 皮膚の外観を改善するための組成物及び方法
WO2019233722A1 (en) 2018-06-08 2019-12-12 Almirall, S.A. Pharmaceutical composition comprising tacrolimus
EP3817717A1 (en) 2018-07-03 2021-05-12 The Procter & Gamble Company Method of treating a skin condition
JP7590462B2 (ja) 2020-06-01 2024-11-26 ザ プロクター アンド ギャンブル カンパニー ビタミンｂ３化合物の皮膚への浸透を改善する方法
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
WO2022187379A1 (en) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0406791B1 (en) * 1989-07-05 1995-02-01 Fujisawa Pharmaceutical Co., Ltd. Aqueous liquid composition for external use
EP0474126B1 (en) * 1990-09-04 1997-03-19 Fujisawa Pharmaceutical Co., Ltd. Ointments containing tricyclic compound
IE65341B1 (en) * 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
JPH06183970A (ja) * 1992-12-16 1994-07-05 Fujisawa Pharmaceut Co Ltd 医薬用組成物
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
DE69525957T2 (de) 1994-10-26 2002-11-14 Novartis Ag Verwendung eines ungesättigten Fettalkohols

Also Published As

Publication number Publication date
JP3396888B2 (ja) 2003-04-14
NO325103B1 (no) 2008-02-04
HUP0000979A3 (en) 2002-10-28
AU6228998A (en) 1998-09-09
HU226163B1 (en) 2008-05-28
BR9807234B1 (pt) 2013-11-05
AU727337B2 (en) 2000-12-07
IL131298A0 (en) 2001-01-28
TW450810B (en) 2001-08-21
AR011846A1 (es) 2000-09-13
NO994003L (no) 1999-10-19
CA2282345C (en) 2008-10-21
PT977565E (pt) 2004-01-30
DE69813542D1 (de) 2003-05-22
ATE237325T1 (de) 2003-05-15
BR9807234A (pt) 2000-04-25
EP0977565A1 (en) 2000-02-09
CN1252721A (zh) 2000-05-10
NO994003D0 (no) 1999-08-19
EA199900749A1 (ru) 2000-04-24
US20020032212A1 (en) 2002-03-14
ES2193515T3 (es) 2003-11-01
EP0977565B1 (en) 2003-04-16
CA2282345A1 (en) 1998-08-27
CN1178656C (zh) 2004-12-08
KR20000070824A (ko) 2000-11-25
WO1998036747A1 (en) 1998-08-27
US6387918B1 (en) 2002-05-14
JP2000513739A (ja) 2000-10-17
DE69813542T2 (de) 2003-11-20
KR100490357B1 (ko) 2005-05-17
DK0977565T3 (da) 2003-08-04
IL131298A (en) 2004-06-20
HK1027957A1 (en) 2001-02-02
EA003580B1 (ru) 2003-06-26

Similar Documents

Publication Publication Date Title
HUP0000979A1 (hu) FK-506 jelű vegyületet és származékait tartalmazó gyógyászati készítmények
DK0956858T3 (da) Farmaceutiske præparater indeholdende lactobacilli til behandling af vaginale infektioner
DK1087960T3 (da) Makrocykliske analoger og fremgangsmåder til deres anvendelse og fremstilling
EE200100495A (et) Sahhariidijääkidega asendatud 1,4-bensotiasepiin-1,1-dioksiidi derivaadid, meetod nende valmistamiseks, ühendite kasutamine ning neid sisaldav ravim
HUP0001170A3 (en) Pharmaceutical compositions containing benzimidazole-2-carbamate derivatives as active ingredients for the treatment of viral infections and cancer
EE05383B1 (et) Polarlkarboksamiidhendid,ÁnendeÁvalmistamineÁjaÁkasutamineÁlipiiditasetÁalandavateÁtoimeainetenaÁningÁneidÁsisaldavÁfarmatseutilineÁkompositsioon
EE04799B1 (et) Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
EE200000589A (et) Kiirlahustuvate efavirenskapslite või -tablettideformuleerimine kasutades superlagundeid
ID22523A (id) Formulasi aerosol obat yang mengandung budesonida
NO20012986L (no) Kontrollert frigivende formulering av natrium divalproex
IT8820073A0 (it) Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione.
EE05255B1 (et) Nahal kasutatavad parasititsiidide vettsisaldavad preparaadid
NO20006646D0 (no) Aminosyrederivater og legemidler inneholdende de samme som aktiv bestanddel
ID29966A (id) Sulfoniloksazolamina-sulfoniloksazolamina sebagai senyawa-senyawa aktif terapi
FI913034A0 (fi) Foerening med magsyrainhiberande effekt och foerfarande foer dess framstaellning.
NO20012578D0 (no) Tilberedninger av vannbaserte rensemidler som danner vesikler og som inneholder aktive midler, fremgangsmåte for deresfremstilling og deres anvendelse
ITMI20011389A0 (it) Formulazioni farmaceutiche acquose di cromoglicato sodico
NO961797D0 (no) Anvendelse av benzopyranderivater for fremstilling av farmasöytiske sammensetninger beregnet for behandling av patologier forbundet med den Na+-uavhengige C1-HCO3-utbytter
NO905327D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive karbamoylderivater.
BR9908796A (pt) Uso de compostos de macrolìdeo, método de tratamento e prevenção de ards, composição farmacêutica e composto macrolìdeo
NO921603D0 (no) Fremgangsmaate til fremstilling av et aktivt findelt agregat for bruk til betong
EE04095B1 (et) Ketoliidide ja nende farmatseutiliselt vastuvõetavate soolade kasutamine farmatseutiliste kompositsioonide valmistamiseks
EE200300065A (et) Meetod peptiidsoolade valmistamiseks, nende peptiidsoolade kasutamine ning neid peptiidsooli sisaldavad farmatseutilised preparaadid
PT1206253E (pt) Preparacoes farmaceuticas solidas contendo nanossois de quitosano e metodo de preparacao

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: ASTELLAS PHARMA INC., JP

Free format text: FORMER OWNER(S): FUJISAWA PHARMACEUTICAL CO., LTD., JP

MM4A Lapse of definitive patent protection due to non-payment of fees